

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
166074	19/NW/0363	250571	Protocol I4V-MC-JAJA (RA-BRIDGE) Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis	No		0			29/05/2019	20/08/2019	08/08/2019	16/08/2019	20/08/2019	27/08/2019	F - No patients seen		Neither
166075	19/NW/0342	264974	A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation	Yes	15/01/2020	6	91	97	21/06/2019	10/10/2019	25/07/2019	11/10/2019	16/10/2019	16/10/2019			Please Select...
166076	19/NW/0317	262846	A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough	No		21			17/09/2019	16/10/2019	12/07/2019	03/10/2019	06/11/2019	06/11/2019	F - No patients seen	No patients eligible over 200 patients screened	Neither
166077	19/SC/0352	255747	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety,	Yes	17/01/2020	12	38	50	12/07/2019	28/11/2019	02/10/2019	28/11/2019	10/12/2019	10/12/2019			Please Select...

			Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis														
166078	18/SC/0666	248460	A multicentre randomised controlled trial assessing the mortality, quality of life, and cost effectiveness of operative rib fixation plus supportive management versus supportive management alone for patients with multiple rib fractures requiring ventilator support.	Yes	20/01/2020	15	34	49	17/09/2019	02/12/2019	09/07/2019	28/11/2019	17/12/2019	17/12/2019			Please Select...
166079	18/SC/0243	240684	HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease	Yes	11/03/2020	6	36	42	02/07/2019	29/01/2020	17/10/2018	16/01/2020	04/02/2020	12/02/2020			Please Select...
166080	19/SC/0422	268966	An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome	Yes	20/02/2020	195	10	205	30/07/2019	30/07/2019	30/09/2019	22/01/2020	10/02/2020	18/02/2020	J - Other	This is a study extension so will not be activated at Aintree until January 2020	Neither
166081	19/NW/0707	272541	A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH).	Yes	19/02/2020	1	6	7	29/11/2019	12/02/2020	23/01/2020	13/02/2020	13/02/2020	14/02/2020			Please Select...

166082	19/EM/0188	261137	A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension	No		7				30/09/2019	10/02/2020	12/09/2020	17/02/2020	17/02/2020	30/06/2020	J - Other	Study halted due to COVID 19.	Neither
166083	19/SC/0347	263849	A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 µg of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps	No		7				30/07/2019	10/02/2020	15/11/2020	17/02/2020	17/02/2020		J - Other	Screening on hold due to COVID-19	Neither
166084	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	08/04/2020	2	12	14		17/03/2020	25/03/2020	17/03/2020	13/03/2020	27/03/2020	30/03/2020			Please Select...
166264	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	Yes	02/05/2020	6	9	15		14/04/2020	17/04/2020	23/07/2020	20/04/2020	23/04/2020	23/04/2020			Please Select...
166265	20/SS/0057	281986	STOP-COVID19	No		6				28/05/2020	17/06/2020	22/05/2020	18/06/2020	23/06/2020		J - Other	Awaiting sponsor green light	Sponsor
166266	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	Yes	08/07/2020	14	40	54		07/05/2020	15/05/2020	03/04/2020	15/05/2020	29/05/2020	03/06/2020			Please Select...